Stifel Financial’s PTC Therapeutics PTCT Stock Holding History

Stifel Financial’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,152	Closed	-$208K	–	3366
2022 Q3	$208K	Buy	+4,152	New	+$203K	﹤0.01%	2934
2021 Q4	–	Sell	-5,774	Closed	-$215K	–	3444
2021 Q3	$215K	Buy	+5,774	New	+$237K	﹤0.01%	3099
2021 Q1	–	Sell	-3,631	Closed	-$222K	–	3272
2020 Q4	$222K	Buy	+3,631	New	+$214K	﹤0.01%	2766
2020 Q3	–	Sell	-4,010	Closed	-$203K	–	2967
2020 Q2	$203K	Buy	+4,010	New	+$197K	﹤0.01%	2579
2020 Q1	–	Sell	-6,501	Closed	-$312K	–	3025
2019 Q4	$312K	Buy	+6,501	New	+$276K	﹤0.01%	2513
2016 Q1	–	Sell	-7,934	Closed	-$257K	–	2349
2015 Q4	$257K	Buy	+7,934	New	+$234K	﹤0.01%	1993
2015 Q3	–	Sell	-5,640	Closed	-$272K	–	2340
2015 Q2	$272K	Buy	+5,640	New	+$329K	﹤0.01%	2008

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Stifel Financial's PTCT Position: Q4 2022 in Review

Stifel Financial sold out of PTC Therapeutics (PTCT) in Q4 2022, closing a stake of 4,152 shares — an estimated $208K sold.

Stifel Financial first reported a position in PTCT in Q2 2015 and held it in 7 quarters. The position peaked at $312K in Q4 2019. 202 funds tracked by Wall St. Rank hold PTCT as of Q4 2022.

Stifel Financial reported no remaining PTC Therapeutics position as of Q4 2022 after selling out during the quarter.
Stifel Financial sold 4,152 PTC Therapeutics shares in Q4 2022, an estimated $208K.
Stifel Financial first reported a position in PTC Therapeutics in Q2 2015 and held it in 7 quarters.
Stifel Financial's PTC Therapeutics position peaked at $312K in Q4 2019.
202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2022.

Based on Stifel Financial's 13F filing for Q4 2022, filed 13 Feb 2023.